Safety, Pharmacokinetics and Pharmacodynamics of Recombinant Chimeric Anti-CD20 Monoclonal Antibody in Patients With B-cell Non-Hodgkin's Lymphoma.

NCT02206308 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

B-cell Non Hodgkin's Lymphoma

Interventions

BIOLOGICAL: Chimeric anti-CD20 monoclonal antibody

Sponsor

Sinocelltech Ltd.